Investor
Stonepine Capital Management, LLC
CIK 0001440771 · filed 2026-05-14 · SEC filing
13F book
$249.7M
Positions
66
20 new · 15 sold
Largest name
7.0%
Verastem, Inc. · VSTM
Est. mark
−$17.1M
Price effect on 46 names still held. Flow $4.38M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Verastem, Inc. | VSTM | 3.3M | $17.5M | 7.0% | −$6.61M | Added−$3.59M |
| Tenax Therapeutics, Inc. | TENX | 975.2K | $15.6M | 6.2% | $45.2K | Added$15.4M |
| Evolus, Inc. | EOLS | 1.76M | $7.23M | 2.9% | −$4.14M | Added−$3.62M |
| Adma Biologics, Inc. | ADMA | 740K | $6.67M | 2.7% | −$6.83M | Held |
| Camp4 Therapeutics Corp | CAMP | 1.39M | $6.13M | 2.5% | −$393.7K | Added$4.73M |
| Nektar Therapeutics | NKTR | 85K | $6.12M | 2.4% | $2.52M | Held |
| Zevra Therapeutics, Inc. | ZVRA | 480K | $4.47M | 1.8% | $172.8K | Cut−$625.4K |
| Corbus Pharmaceuticals Hldgs | — | 383.5K | $3.6M | 1.4% | $479.3K | Cut$426.8K |
| Abeona Therapeutics Inc. | ABEO | 746.6K | $3.34M | 1.3% | −$560.5K | Added−$394.4K |
| Kazia Therapeutics Ltd | KZIA | 345.2K | $2.57M | 1.0% | $189.8K | Cut−$603.7K |
| AN2 Therapeutics, Inc. | ANTX | 713.8K | $2.44M | 1.0% | $1.43M | Added$1.73M |
| Sol-Gel Technologies Ltd. | SLGL | 27.8K | $2.2M | 0.9% | — | New |
| Xoma Royalty Corporation | — | 69.5K | $2.18M | 0.9% | $332.2K | Cut−$877.6K |
| Aytu Biopharma, Inc | AYTU | 792.3K | $2.16M | 0.9% | $103K | Cut$47.3K |
| Curis Inc | CRIS | 3.73M | $2.04M | 0.8% | −$26.1K | Added$1.98M |
| TELA Bio, Inc. | TELA | 2.62M | $1.62M | 0.7% | −$1.32M | Added−$1.15M |
| Inhibikase Therapeutics, Inc. | IKT | 957.2K | $1.61M | 0.6% | −$354.2K | Cut−$3.21M |
| Crescent Biopharma, Inc. | CBIO | 85K | $1.56M | 0.6% | $553.3K | Cut$521.5K |
| Adicet Bio, Inc. | ACET | 222K | $1.51M | 0.6% | −$354.2K | Added−$341K |
| X4 Pharmaceuticals, Inc | XFOR | 335.3K | $1.38M | 0.6% | $43.6K | Cut−$989.5K |
| Okyo Pharma Ltd | OKYO | 850K | $1.37M | 0.5% | — | New |
| Heron Therapeutics Inc | — | 1.4M | $1.12M | 0.4% | −$618.8K | Added−$487.3K |
| Pulmonx Corp | LUNG | 768.3K | $991.1K | 0.4% | −$447.5K | Added−$83.9K |
| In8bio, Inc. | INAB | 663.4K | $981.9K | 0.4% | −$141.8K | Added$596K |
| Surrozen Inc | — | 33K | $961.4K | 0.4% | $215.5K | Cut−$1.61M |
| CytomX Therapeutics, Inc. | CTMX | 200K | $940K | 0.4% | — | New |
| PMV Pharmaceuticals, Inc. | PMVP | 708.1K | $878K | 0.4% | −$7.08K | Cut−$560.4K |
| BioAge Labs, Inc. | BIOA | 50K | $874.5K | 0.4% | $191.7K | Added$279.1K |
| Connect Biopharma Hldgs Ltd | — | 310K | $812.2K | 0.3% | — | New |
| Radiopharm Theranostics Ltd | — | 51M | $739K | 0.3% | −$111.9K | Held |
| Maxcyte, Inc. | MXCT | 1M | $705.8K | 0.3% | −$397.5K | Added−$21.2K |
| Codexis, Inc. | CDXS | 418K | $681.3K | 0.3% | −$0 | Added$263.9K |
| Boundless Bio, Inc. | BOLD | 597.7K | $657.5K | 0.3% | −$59.8K | Cut−$194.6K |
| Cybin Inc. | HELP | 134.1K | $643.5K | 0.3% | −$453.1K | Cut−$2.14M |
| Zentalis Pharmaceuticals, Inc. | ZNTL | 269.1K | $629.7K | 0.3% | $266.4K | Cut$3.7K |
| Pasithea Therapeutics Corp | — | 831.3K | $616.7K | 0.2% | −$150.8K | Added$261.8K |
| Satellos Bioscience Inc. | MSLE | 100K | $563K | 0.2% | — | New |
| Phathom Pharmaceuticals, Inc. | PHAT | 50K | $555.6K | 0.2% | — | New |
| OnKure Therapeutics, Inc. | OKUR | 132.6K | $548.9K | 0.2% | — | New |
| Xilio Therapeutics, Inc. | XLO | 64.2K | $539.6K | 0.2% | — | New |
| Verrica Pharmaceuticals Inc. | VRCA | 99.7K | $527.6K | 0.2% | −$301.2K | Cut−$2.41M |
| Candel Therapeutics, Inc. | CADL | 102.5K | $502.3K | 0.2% | — | New |
| Precision Optics Corp Inc Ma | — | 100K | $439K | 0.2% | — | New |
| Quoin Pharmaceuticals, Ltd. | QNRX | 53.5K | $352.8K | 0.1% | −$418.6K | Cut−$775.4K |
| Establishment Labs Hldgs Inc | — | 6K | $340.7K | 0.1% | — | New |
| Upstream Bio, Inc. | UPB | 35K | $315K | 0.1% | — | New |
| Opus Genetics, Inc. | IRD | 68.7K | $312.5K | 0.1% | — | New |
| Arvinas, Inc. | ARVN | 27.5K | $291.5K | 0.1% | — | New |
| Pliant Therapeutics, Inc. | PLRX | 224.7K | $283.1K | 0.1% | $8.99K | Cut$2.4K |
| Janux Therapeutics, Inc. | JANX | 20K | $278K | 0.1% | $2K | Held |
| Omniab Inc | — | 164K | $257.6K | 0.1% | −$45.9K | Cut−$1.04M |
| Xeris Biopharma Holdings, Inc. | XERS | 40K | $232.2K | 0.1% | — | New |
| Compugen Ltd | CGEN | 104.3K | $222.2K | 0.1% | $62.6K | Cut−$245.1K |
| Neumora Therapeutics, Inc. | NMRA | 100K | $195K | 0.1% | — | New |
| Sab Biotherapeutics Inc | — | 50K | $191.5K | 0.1% | — | New |
| SI-BONE, Inc. | SIBN | 15K | $189K | 0.1% | — | New |
| Edesa Biotech, Inc. | EDSA | 30K | $156.9K | 0.1% | $114.3K | Cut−$819.4K |
| CNS Pharmaceuticals, Inc. | CNSP | 61K | $145.8K | 0.1% | −$139.6K | Added−$110.6K |
| Processa Pharmaceuticals, Inc. | PCSA | 55K | $138.9K | 0.1% | −$4.37K | Added$103.4K |
| Cabaletta Bio, Inc. | CABA | 50K | $134.5K | 0.1% | $25K | Cut−$240.2K |
| Kalaris Therapeutics, Inc. | KLRS | 20.4K | $117.7K | 0.0% | — | New |
| Eledon Pharmaceuticals, Inc. | ELDN | 35K | $107.8K | 0.0% | $55K | Cut−$1.24M |
| Ovid Therapeutics Inc. | OVID | 40K | $88.8K | 0.0% | $23.6K | Cut−$78.1K |
| Evaxion As | — | 19.7K | $73.3K | 0.0% | −$20.7K | Cut−$22.1K |
| Mannkind Corp | MNKD | 16.3K | $39.9K | 0.0% | −$52.5K | Cut−$449.7K |
| BioAtla, Inc. | BCAB | 65.4K | $10.5K | 0.0% | — | New |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.